natgillin/translations-raw huggingface dataset:
Non-clinical studies of the toxicology of Rasitrio alone have not been conducted as these studies have been conducted for the individual components.
Nekliničnih študij toksičnega vpliva samega zdravila Rasitrio niso izvajali, saj so tovrstne študije izvedli za posamezne učinkovine.
Non-clinical studies suggest no specific hazard for humans on the basis of single-and repeat-dose studies, with the exception of transient but fully reversible infertility in male rats associated with migalastat treatment.
Predklinične študije s enkratnimi in ponavljajočimi odmerki niso pokazale nobene posebne nevarnosti za ljudi, povezane z zdravljenjem z migalastatom, razen prehodne, vendar v celoti reverzibilne neplodnosti pri podganjih samcih.
Non-clinical toxicology studies, including conventional studies of safety pharmacology, repeated-dose toxicity, genotoxicity, developmental toxicity and juvenile toxicity, have been conducted with raltegravir, in mice, rats, dogs and rabbits.
Predklinične toksikološke študije, vključno z običajnimi študijami farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, škodljivega vpliva na razvoj in juvenilnimi študijami so bile z raltegravirjem izvedene na miših, podganah, psih in kuncih.
non-competitively antagonises adrenergic activities (Class II).
Nekompetitivno antagonizira adrenergične učinke (III. skupina).
Non-cutaneous malignancy
Nekožni malignom
Non-cutaneous malignancy
Nekožni malignomi
Non-cutaneous secondary/recurrent malignancy
Nekožni sekundarni/ponovni malignomi
Non-Cutaneous Squamous Cell Carcinoma (non-cuSCC)
Ploščatocelični karcinom, ki se ne nahaja na koži
Non-defibrotide treated
Brez defibrotida
Non-depolarising skeletal muscle relaxants (e.g.  tubocurarine)
nedepolarizacijski relaksanti skeletnih  mišic (npr. tubokurarin)
Non-depolarising skeletal muscle relaxants (e.g.  tubocurarine)
nedepolarizacijski relaksanti skeletnih mišic (npr. tubokurarin)
Non-diabetic studies
študije pri nediabetikih
Non-fatal PE
ne-fatalna PE
non-fatal stroke, or hospitalization for unstable angina
mrtnega izida, možganska kap brez smrtnega izida ali sprejem v bolnišnico zaradi nestabilne angine pektoris
non-gastrointestinal fistula (including tracheal, pneumomediastinum, tracheo-oesophageal), pulmonary embolism, respiratory tract haemorrhage (including pulmonary, bronchial, tracheal), pneumonia aspiration
ne-gastrointestinalna fistula (vključno s trahealno, pnevmomediastinumom, traheo-ezofagealno), pljučna embolija, krvavitev v dihalih (vključno s pljuči, sapnicami, sapnikom), aspiracijska pljučnica
Non-GI fistula
ne-GI fistula
Non-haematologic
Nehematološka merila
Non-haematologic tissues seem to be unaffected, explaining the low incidence of non-haematopoietic toxicity of cladribine
Videti je, da nehematološka tkiva niso prizadeta, kar razlaga nizko pojavnost nehematopoetske toksičnosti klabridina.
Non-haematological adverse reactions (excluding laboratory abnormalities) that are reported in at least 5% of the patients in Tasigna clinical studies are shown in Table 2.
V preglednici 2 so prikazani nehematološki neželeni učinki (razen laboratorijskih nepravilnosti), o katerih so poročali pri vsaj 5 % bolnikov iz kliničnih študij z zdravilom Tasigna.
Non-haematological adverse reactions (excluding laboratory abnormalities) that are reported in at least 5% of the patients treated with 300 mg of nilotinib twice daily in the randomised Phase III study are shown in Table 2.
V preglednici 2 so prikazani nehematološki neželeni učinki (razen laboratorijskih nepravilnosti), o katerih so poročali pri vsaj 5 % bolnikov, ki so v randomizirani študiji faze III prejemali 300 mg nilotiniba dvakrat dnevno.
Non-haematological toxicities should have resolved to Grade 1 or baseline
Ne-hematološke toksičnosti se morajo vrniti na 1. stopnjo ali vrednost pred začetkom zdravljenja.
Non-haematological toxicities should have resolved to Grade 1 or baseline
Nehematološke toksičnosti se morajo povrniti na 1. stopnjo ali na stanje pred začetkom zdravljenja.
Non-haematological toxicities should have resolved to Grade 1 or baseline.
Ne-hematološke toksičnosti se morajo povrniti na 1. stopnjo ali na stanje pred začetkom zdravljenja.
Non-haematological toxicities should have resolved to Grade 1 or baseline.
Nehematološke toksičnosti se morajo povrniti na 1. stopnjo ali stanje pred začetkom zdravljenja.
Non-haematological:
Nehematološki:
Non-HDL-C
Holesterol ne- HDL
Non-HDL-C
Holesterol ne-HDL
Non-HDL-C
Ne-HDL
Non-HDL-C
Ne-HDL-holesterol
non-HDL-cholesterol, mean % change from baseline
ne-HDL-holesterol, povprečna sprememba v % od izhodišča
Non-Hodgkin’s Lymphoma
ne-Hodgkinovega limfoma
Non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia
Ne-Hodgkinov limfom in kronična limfocitna levkemija
Non-infectious hepatitis
neinfektivni hepatitis
Non-infectious periostitis with elevated fluoride and alkaline phosphatase levels has been reported in transplant patients.
pri bolnikih s presadkom so poročali o neinfktivnem periostitisu, ki ga spremlja zvišanje ravni fluorida in alkalne fosfataze.
Non-infectious uveitis affecting the back of the eye For more information, please see below.
ulceroznega kolitisa neinfekcijski uveitis, ki prizadene zadnji del očesa Več informacij je navedenih v nadaljevanju.
Non-inferiority criteria were met if the lower bound of the two- sided 98.3 % confidence interval for the difference in complete response rates of oral palonosetron dose minus approved intravenous formulation was larger than -15 %.
Merila ne-manjvrednosti so bila izpolnjena, če je bila spodnja meja dvosmernega 98,3-odstotnega intervala zaupanja za razliko v celotnih odzivnostih na peroralni odmerek palonosetrona minus odobreni intravenski pripravek večja od -15 %.
Non-inferiority in HbA1c change from baseline to end-of-trial was confirmed in all studies against all comparators, when treating patients to target.
Neinferiornost zdravila Ryzodeg glede spremembe HbA1c med začetkom in koncem preskušanja je bila ugotovljena v vseh preskušanjih v primerjavi z vsemi primerjanimi zdravili, kjer so zdravili bolnike do ciljnih vrednosti.
non-inferiority margin
meja enakovrednosti
Non-inferiority of SANCUSO versus oral granisetron was confirmed, with complete control (CC) achieved in 60.2% of patients in the SANCUSO arm and 64.8% of patients receiving oral granisetron in the per protocol set (difference -4.89%; 95% confidence interval –12.91% to +3.13%; n=284 transdermal patch, n=298 oral).
Potrdili so neinferiornost zdravila SANCUSO v primerjavi s peroralnim granisetronom, popolno kontrolo (CC) so dosegli pri 60,2 % bolnikov v kraku z zdravilom SANCUSO in 64,8 % bolnikov, ki so prejemali peroralni granisetron v skupini po protokolu (razlika -4.89 %; 95-odstotni interval zaupanja –12.91 % do +3,13 %; n=284 transdermalni obliž, n=298 peroralno).
Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival and overall survival in the eligible per-protocol population.
V populaciji, ki je bila primerna glede na protokol raziskave, je bila v celokupni primerjavi glede na preživetje brez napredovanja bolezni in celokupno preživetje dokazana neinferiornost skupin, ki so se zdravile po shemi XELOX, v primerjavi s skupinami, ki so se zdravile po shemi FOLFOX-4.
Non-inferiority p-value (HR)
0,67 (0,48–0,96)
Non-inferiority p-value (HR)
Prednostna p-vrednost (RT)
Non-insulin anti- hyperglycaemic medicinal products
neinsulinskimi antihiperglikemičnimi zdravili
Non-insulin anti-hyperglycaemic medicinal products
Neinsulinskimi antihiperglikemičnimi zdravili
Non-interventional PASS: In order to investigate the long term safety and efficacy of Strimvelis gene therapy, the MAH should conduct and submit the results of a long term prospective, non-interventional follow up study using data from a registry of patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) treated with Strimvelis.
Neintervencijska študija o varnosti zdravila po pridobitvi dovoljenja za promet: Za proučitev dolgoročne varnosti in učinkovitosti genskega zdravljenja z zdravilom Strimvelis mora MAH izvesti in predložiti rezultate dolgoročne prospektivne, neintervencijske spremljevalne študije z uporabo podatkov iz registra bolnikov s hudo kombinirano imunsko pomanjkljivostjo zaradi pomanjkanja adenozin deaminaze (ADA-SCID), zdravljenih z zdravilom Strimvelis.
Non-interventional post authorisation safety study (PASS): In order to evaluate the long- term safety outcomes of dinutuximab in high-risk neuroblastoma patients (including central and peripheral nervous system, prevalence of organ dysfunction, long-term effects on growth and endocrine development, hearing loss, cardiac toxicity and survival data) the applicant should conduct and submit the results of a safety registry.
tveganjem (vključno s centralnim in perifernim živčnim sistemom, prevladujočim nedelovanjem organov, dolgotrajnimi učinki na rast in endokrini razvoj, izgubo sluha, srčno toksičnostjo in podatki o preživetju), mora predlagatelj voditi in predložiti rezultate registra o varnosti.
Non-interventional post-authorisation safety study (PASS) in order to further investigate the tolerability of Pandemic influenza vaccine H5N1 MedImmune and estimate the incidence of adverse reactions of special interest in children and adolescents.
Neintervencijska študija o varnosti zdravila po pridobitvi dovoljenja za promet z zdravilom (PASS) za dodatno proučitev prenašanja Cepiva proti pandemski gripi H5N1 MedImmune in oceno pojavnosti neželenih učinkov posebnega pomena pri otrocih in mladostnikih.
Non-interventional post-authorisation safety study (PASS): LAL Deficiency Registry: Non-interventional, multicentre, prospective disease and clinical outcome registry of patients with Lysosomal Acid Lipase Deficiency to further understand the disease, its progression and any associated complication, and to evaluate the long-term efficacy (normalisation of hepatic function) and safety of Kanuma (in particular hypersensitivity reactions, including anaphylaxis, and anti-drug antibodies development potentially impacting response to drug) according to agreed protocol.
Neintervencijska študija o varnosti zdravila po pridobitvi dovoljenja za promet z zdravilom (PASS): Register o pomanjkanju LAL: Neintervencijski, multicentrični, bodoči register bolezni in kliničnih izidov pri bolnikih s pomanjkanjem lizozomalne kisle lipaze za nadaljnje razumevanje bolezni, njenega napredovanja in vseh morebitnih zapletov, ter za ocenjevanje dolgoročne učinkovitosti (normalizacija delovanja jeter) in varnosti zdravila Kanuma (zlasti glede preobčutljivostnih reakcij, vključno z anafilaksijo, in razvoja protiteles protui zdravilu, ki potencialno vplivajo na odziva na zdravilo) v skladno z dogovorjenim protokolom.
Non-interventional post-authorisation safety study (PASS): Study 20150136: an observational study of blinatumomab safety and effectiveness, utilisation, and treatment practices*
Neintervencijska študija o varnosti zdravila po pridobitvi dovoljenja za promet z zdravilom (PASS): Študija 20150136: Opazovalna študija o varnosti in učinkovitosti blinatumomaba, uporabi in praksah zdravljenja
Non-interventional study (NIS) to gather further safety data, in order to
Neintervencijska študija (NIS) za pridobitev nadaljnjih podatkov o varnosti, s
Non-invasive examination of the treated skin by reflectance confocal microscopy have shown that the skin changes induced by ingenol mebutate were reversible, with almost complete normalisation of all measured parameters on day 57 after treatment, which is supported also by clinical findings and studies in animals.
Neinvazivni pregled zdravljene kože z odbojno konfokalno mikroskopijo je pokazal, da so bile kožne spremembe, ki jih je povzročil ingenol mebutat, reverzibilne, saj je 57. dan po zdravljenju prišlo do skoraj popolne normalizacije vseh izmerjenih parametrov, kar potrjujejo tudi klinične ugotovitve in študije na živalih.
Non-invasive, mildly to moderately painful, procedures and examinations which require restraint, sedation and analgesia in dogs and cats.
Neinvazivni, blago do zmerno boleči posegi in pregledi psov in mačk, pri katerih so potrebni mirovanje, sedacija in analgezija.
Non-linearity:
Nelinearnost:
Non-liposomal irinotecan was shown to cause atrophy of male and female reproductive organs after multiple daily irinotecan doses in animals (see section 5.3).
Dokazali so, da neliposomski irinotekan po večkratnih dnevnih odmerkih irinotekana pri živalih povzroča atrofijo reproduktivnih organov samcev in samic (glejte poglavje 5.3).
Non-malignant ovarian macrocysts (with symptoms such as pelvic pain, bleeding) have been described.
Opisane so bile nemaligne makrociste na jajčnikih (s simptomi, kot sta medenična bolečina in krvavitev).
Non-melanoma skin cancer* Basal cell carcinoma Squamous cell carcinoma
nemelanomski kožni raki* bazalnocelični karcinom skvamozni karcinom
non-melanoma skin cancer, most frequently squamous cell and basal cell skin cancer
nemelanomski kožni rak, najpogosteje ploščatocelični ali bazalnocelični rak
Non-missing FibroTest results are mapped to Metavir scores according to: 0-0.31 = F0-F1; 0.32-0.58 = F2; 0.59-1.00 = F3-F4.
Nemanjkajoči rezultati FibroTest so kartirani v rezultate Metavir glede na: 0–0,31 = F0–F1; 0,32–0,58 = F2; 0,59– 1,00 = F3–F4.
Non-mycobacterial species
Bakterije, ki ne spadajo med mikobakterije
Non-neutralising anti factor VIII antibody positive
pozitivna nenevtralizirajoča protitelesa za faktor VIII
Non-neutralising antibodies have been seen in 4 of the 56 exposed patients with congenital FXIII deficiency.
Nenevtralizirajoča protitelesa so opazili pri 4 od 56 izpostavljenih bolnikov s prirojenim pomanjkanjem FXIII.
Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs)
Ne-nukleozidni zaviralci reverzne transkriptaze (NNRTI)
Non-nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)
Nenukleozidni analogi zaviralcev reverzne transkriptaze
Non-nucleoside Reverse Transcriptase Inhibitors
Nenukleozidni zaviralci reverzne transkriptaze
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Drugi nenukleozidni zaviralci reverzne transkriptaze (NNRTI, Non-Nucleoside Reverse Transcriptase Inhibitors):
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Ne-nukleozidni zaviralci reverzne transkriptaze (NNRTI)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nenukleozidni zaviralci reverzne transkriptaze
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nenukleozidni zaviralci reverzne transkriptaze (NNRTI)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs):
Nenukleozidni zaviralci reverzne transkriptaze (NNRTI-ji):
Non-obese
Telesna masa ni prekomerna
non-perforated blister (alu/alu)
Neperforiran pretisni omot (Alu/Alu)
non-perforated calendar blister (alu/alu)
Neperforiran koledarski pretisni omot (Alu/Alu)
Non-prescribed overdoses had a median of 6 mg.
Pri nepredpisanih prevelikih odmerkih je bila mediana 6 mg.
Non-Procedural PLATO Major
PLATO hude, nepovezane s postopki
Non-Procedural PLATO Major + Minor
PLATO hude in blage, nepovezane s postopki
Non-radiographic axial spondyloarthritis (nr-Axial SpA)
Neradiografski aksialni spondiloartritis (nr-aksialni SpA)
Non-radiographic axial spondyloarthritits
aksialni spondiloartritis brez radiografskega dokaza
Non-responder
Brez odziva
Non-responder Imputation (NRI) is used for patients who escaped therapy or had missing data.
Za bolnike, ki so zapustili zdravljenje ali so njihovi podatki pomanjkljivi, uporabljamo metodo imputacije manjkajočih podatkov.
Non-responder imputation used for missing binary endpoint
ASAS: ocena po po kriterijih Mednarodnega združenja za spondiloartritis (angl.
Non-responder imputation used for missing binary endpoint.
ACR: po kriterijih Ameriške akademija za revmatologijo (angl.
Non-responder, n (%)
odzivajo, n (%)
Non-responders
Neodzivni bolniki
Non-responders to prior therapy with pegylated interferon alpha/ribavirin were less likely to achieve a week 12 response to retreatment than non-responders to non-pegylated interferon alpha/ribavirin (12.4% vs.
Pri bolnikih, ki se niso odzvali na predhodno zdravljenje s pegiliranim interferonom alfa/ribavirinom, je bila verjetnost, da se bodo odzvali na ponovno zdravljenje v 12. tednu, manjša kot pri tistih, ki se niso odzvali na zdravljenje z nepegiliranim interferonom alfa/ribavirinom (12,4 % v primerjavi z 28,6 %).
Non-responders to prior therapy with pegylated interferon alpha/ribavirin were less likely to achieve a week 12 response to retreatment than non-responders to nonpegylated interferon alpha/ribavirin (12.4 % vs.
Pri bolnikih, ki se niso odzvali na predhodno zdravljenje s pegiliranim interferonom alfa/ribavirinom, je bila verjetnost, da se bodo odzvali na ponovno zdravljenje v 12. tednu, manjša kot pri tistih, ki se niso odzvali na zdravljenje z nepegiliranim interferonom alfa/ribavirinom (12,4 % vs.
Non-response
brez odziva na zdravljenje
Non-response
Neodzivni
non-selective phosphodiesterase inhibitors like pentoxifylline, selective phosphodiesterase 3 (PDE3) inhibitors like cilostazol or anagrelide,
neselektivni zaviralci fosfodiesteraze, kot je pentoksifilin, selektivni zaviralci fosfodiesteraze 3 (PDE 3), kot sta cilostazol ali anagrelid,
non-selective phosphodiesterase inhibitors, such as pentoxifylline, selective phosphodiesterase (PDE 3) inhibitors, such as cilostazol or anagrelide,
neselektivne zaviralce fosfodiesteraze, kot je pentoksifilin, selektivne zaviralce fosfodiesteraze (PDE 3), kot sta cilostazol ali anagrelid,
Non-serious allergic reactions associated with Humira were uncommon during clinical trials.
Z zdravilom Humira povezane alergijske reakcije, ki niso bile resne, so se v kliničnih študijah pojavljale občasno.
Non-serious cases of keratitis have been observed in 0.2 to 0.7% of clinical trial patients.
Pri 0,2 do 0,7 % bolnikov v kliničnih preskušanjih so zabeležili primere keratitisa, ki niso bili resni.
Non-serious infections with usual response to standard care and not requiring discontinuation of Cosentyx were reported in the remaining 3 cases.
V preostalih 3 primerih so poročali o okužbah, ki niso bile opredeljene kot resne in pri katerih je prišlo do običajnega odziva na standardno zdravljenje, prekinitev uporabe zdravila Cosentyx pa ni bila potrebna.
Non-small cell lung cancer (NSCLC)
Nedrobnocelični rak pljuč
Non-Small Cell Lung Cancer (NSCLC):
Nedrobnocelični rak pljuč:
Non-small cell lung cancer (Tarceva administered as monotherapy):
Nedrobnocelični rak pljuč (zdravilo Tarceva kot samostojno zdravljenje):
Non-Small Cell Lung Cancer Squamous NSCLC
Nedrobnocelični pljučni rak Ploščatocelični NSCLC
Non-species related breakpoints2
Mejne vrednosti, nepovezane z vrsto2
Non-specific skin rashes
nespecifični kožni izpuščaji
Non-squamous NSCLC
Neskvamozni NSCLC
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q- wave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca):zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom brez elevacije ST-spojnice (nestabilna angina ali miokardni infarkt brez Q-zobca): zdravljenje začnemo z enkratnim udarnim 300-mg odmerkom klopidogrela in nadaljujemo s 75-mg odmerkom enkrat na dan (75 mg do 325 mg ASA na dan).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen stent po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA – acetylsalicylic acid).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca): zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca):zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca): zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).
Non-Steroidal Anti-
Nesteroidna protivnetna
Non-steroidal anti- inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (>3 g/day), and non-  selective NSAIDs
nesteroidna protivnetna zdravila (NSAIDs), vključno s selektivnimi zaviralci ciklooksigenaze-2 (z zaviralci COX-2), acetilsalicilno kislino (>3 g/dan) in neselektivnimi NSAIDs
Non-steroidal anti- inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (>3 g/day), and non- selective NSAIDs
nesteroidna protivnetna zdravila (NSAIDs), vključno s selektivnimi zaviralci ciklooksigenaze-2 (z zaviralci COX-2), acetilsalicilno kislino (>3 g/dan) in neselektivnimi NSAIDs
Non-steroidal anti- inflammatory medicines (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (>3 g/day), and non- selective NSAIDs
nesteroidna protivnetna zdravila (NSAIDs), vključno s selektivnimi zaviralci ciklooksigenaze-2 (z zaviralci COX-2), acetilsalicilno kislino (>3 g/dan) in neselektivnimi NSAIDs
Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, diclofenac) (used for treating pain and inflammation)
nesteroidna protivnetna zdravila (npr. ibuprofen, diklofenak) (uporabljajo se proti bolečini in za zdravljenje vnetja)
Non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid > 3 g/day), and non-selective NSAIDs
Nesteroidna protivnetna zdravila (NSAID), vključno s selektivnimi zaviralci COX-2, acetilsalicilno kislino (> 3 g/dan) in neselektivnimi NSAID
Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac or celecoxib (medicines to relieve pain and inflammation)
nesteroidna protivnetna zdravila, kot so ibuprofen, diklofenak ali celekoksib (zdravila za lajšanje bolečine in vnetja),
Non-steroidal anti-inflammatory drugs (NSAIDs): Concomitant administration with chronic NSAIDs has not been studied.
Nesteroidna protivnetna zdravila (NSAIDs): Študij sočasnega dajanja s kroničnim zdravljenjem z NSAIDs niso opravili.
non-steroidal anti-inflammatory drugs,
nesteroidna protivnetna zdravila,